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Summary Stathmin is a highly conserved cytosolic phosphoprotein that destabilizes microtubules. Stathmin, which has been proposed as a
relay protein integrating diverse cell signalling pathways, acts in vitro as a tubulin-sequestering protein, and its activity is dramatically reduced
by phosphorylation. Interestingly, stathmin expression and phosphorylation are regulated during the control of cell growth and differentiation,
and there is much evidence suggesting that in vivo stathmin plays a role in the control of microtubule dynamics during mitosis. Stathmin may
thus be considered as one of the key regulators of cell division. We examined 50 human primary breast tumours for stathmin mRNA and
protein expression and screened for abnormalities in the chromosome region harbouring the stathmin gene. Overexpression of stathmin was
found in 15 tumours (30%). At the present stage, no clear correlation emerged between stathmin expression and several prognosis markers.
Interestingly, perfect matching was observed between stathmin mRNA overexpression, protein overexpression and strong staining for
stathmin on paraffin-embedded tumour sections when specimens were available. Furthermore, a tentative link between loss of heterozygosity
(LOH) in the 1 p32-1pter region and stathmin overexpression was observed. Our results suggest that stathmin might play a role in breast
carcinogenesis and that stathmin-overexpressing tumours may represent a new subtype of breast cancer.
Keywords: human breast cancer; stathmin; protein phosphorylation; Western blotting; DNA; RNA
Stathmin (Sobel et al, 1989), also referred to as p19 (Pasmantier et
al, 1986), prosolin (Cooper et al, 1989), p18 (Hanash et al, 1988),
pp20 (Peyron et al, 1989) and Opl8 (Hailat et al, 1990), is a
ubiquitous cytosolic phosphoprotein whose expression and
phosphorylation is modulated during the activation of a wide
diversity of signal transduction pathways, such as cascades trig-
gered by hormones (Sobel and Tashjian, 1983; Beretta et al, 1988,
1989a), growth factors (Doye et al, 1990) and neurotransmitters
(Chneiweiss et al, 1992). Stathmin has been proposed as a relay
protein integrating diverse cell signalling pathways (Sobel, 1991).
Numerous data suggest that stathmin dysfunction might be asso-
ciated with tumorigenesis. Stathmin expression and phosphoryla-
tion are probably linked to the control ofcell differentiation (Doye
et al, 1992; Di Paolo et al, 1996) and proliferation (Braverman et al,
1986; Cooper et al, 1990; Koppel et al, 1993; Balogh et al, 1996)
(for a review see Sobel, 1991). The state of stathmin phosphoryla-
tion changes markedly during the cell cycle (Strahler et al, 1992;
Brattsand et al, 1994), and cell division also appears to require
multisite phosphorylation of this protein (Larsson et al, 1995;
Lawler et al, 1997). More obviously, it has recently been shown
that stathmin interferes with the dynamic instability of micro-
tubules by destabilizing them in vitro (Belmont and Mitchison,
1996) and in vivo (Marklund et al, 1996). We demonstrated that
this phenomenon is related to a direct interaction of stathmin with
tubulin dimers, leading to the sequestration of tubulin in a two-
tubulin heterodimer-one-stathmin complex (T2S) (Curmi et al,
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1997; Jourdain et al, 1997). Furthermore, it has been shown that
phosphorylation of stathmin dramatically reduces its affinity for
tubulin and its microtubule-destabilizing activity (Marklund et al,
1996; Curmi et al, 1997; Di Paolo et al, 1997; Horwitz et al, 1997;
Larsson et al, 1997), giving an additional clue to the mechanisms of
the in vivo control of microtubule reorganization during mitosis.
Finally, the stathmin gene maps to lp35-36.1 (Ferrari et al, 1990),
in a region (lp32-lpter) thought to harbour at least one tumour-
suppressor gene (Bieche et al, 1994).
The status ofstathmin in tumours remains unclear, but a number
of reports support its participation in carcinogenesis. Over-
expression of the protein has been regularly observed in acute
leukaemia (Hanash et al, 1988; Brattsand et al, 1993; Ghosh et al,
1993; Luo et al, 1994), lymphomas (Brattsand et al, 1993; Ghosh
et al, 1993; Nylander et al, 1995) and various carcinomas (Ghosh
et al, 1993), while, in neuroblastomas, stathmin overexpression
has been found to correlate negatively with N-myc amplification
(Hailat et al, 1990). However, only a few of the above-mentioned
reports examined stathmin phosphorylation in these tumours. For
example, stathmin is not phosphorylated in acute leukaemia
(Hanash et al, 1988), and, in neuroblastomas, a negative correla-
tion between stathmin phosphorylation and N-mvc amplification
has been reported (Hailat et al, 1990).
The aim ofthis study was to investigate the status of stathmin in
a series ofhuman malignant breast tumours. We studied, in parallel,
stathmin genomic DNA, mRNA and protein (expression, phos-
phorylation and immunohistolocalization) to determine whether
alterations of the gene or its product are involved in this very
common human cancer. We show here that stathmin is overex-
pressed in about one-third of breast carcinomas. Furthermore, we
also observed a trend towards a link between stathmin overexpres-
sion and loss of heterozygosity (LOH) in the chromosomal
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lp32-lpter region. Together, our results strengthen the idea that
stathmin dysfunction may be related to some mechanisms of the
breast tumorigenic process. Stathmin overexpression may thus
delineate a new subgroup ofbreast cancer.
PATIENTS AND METHODS
Tissue and blood samples
Fifty primary breast tumour samples classified grade I-III (I,n = 2;
IL,n = 23; III,n = 25), were obtained atthe Centre Rene Huguenin (St
Cloud, France). Adjacent normal breast tissue was also taken from
six ofthe 50 patients. Normal breast tissue specimens were obtained
from eight women undergoing cosmetic breast surgery. Tissue
samples were immediately placed in liquid nitrogen until extraction
of mRNA and protein. Breast tumour specimens were also fixed in
10% neutral buffered formaldehyde or Bouin and embedded in
paraffin for standard light microscopy. Morphological studies were
performed on routinely processed tissue sections and the same
blocks were used for immunohistochemical detection. Blocks were
cut into 3-gm sections, stained with haematoxylin-eosin and saffron
(HES) and observed under the light microscope. This confirmed
the representative nature of the tumour specimens. Immuno-
histochemistry was performed on 14 fixed, paraffin-embedded
tissue sections from the same tumour specimen.
Evaluation of 'classical' prognostic factors
The macroscopic size, histological type and steroid hormone
receptor status ofeach tumour, and the number ofpositive axillary
nodes, were established at the time of surgery. The malignancy of
infiltrating carcinomas was scored according to Bloom and
Richardson's histoprognostic grading (Bloom and Richardson,
1957). Oestrogen and progesterone receptors were assayed as
described by the European Organization for Research and
Treatment for Cancer (EORTC Breast Cooperative Group
Revision, 1980), with a detection threshold of 10 fmol mg-'
cytosolic protein.
DNA analysis
DNA was extracted from tumour tissue and blood leucocytes from
each patient, according to standard methods (Sambrook et al, 1989).
Southern blotanalysis
Ten micrograms of DNA from each sample was digested with the
appropriate restriction endonuclease. The resulting fragments
were separated by electrophoresis in agarose gel (leucocyte and
tumour DNA samples from each patient were run in adjacent
lanes), and blotted onto nylon membrane filters (Hybond N+,
Amersham UK) according to standard techniques. The membrane
filters were hybridized with nick-translated 32P-labelled probes,
washed and autoradiographed at-80°C.
Polymorphic DNA probes used in this study to detect LOH on
lp32-pter are D1S80, D1S76, D1S7, DIS57 and MYCLI. A
detailed description is given in Bieche et al (1994).
Determination ofallele loss
Paired normal and tumour DNA from each patient was analysed
using probe-enzyme combinations which identify restriction
fragment length polymorphisms (RFLPs) in a large proportion of
individuals. Normal DNA samples which were polymorphic at a
given locus were considered 'informative', whereas homozygous
samples were 'uninformative'. The signal intensity of fragments
was determined by visual examination and confirmed by densito-
metry. The amount ofpaired normal and tumour DNA loaded onto
the lanes (assessed with control probes on other chromosomes)
was taken into account when judging the loss of allele in the
tumour DNA. LOH was considered to occur when the intensity of
the allele in the tumour DNA was less than 50% of that in corre-
sponding normal tissue DNA. This partial loss is due either to
contaminating normal tissue or to tumour heterogeneity.
RNA analysis and quantification
RNA was extracted from normal and tumour tissue by using the
lithium chloride/urea method (Auffray and Rougeon, 1980). Ten
micrograms of RNA was fractionated by electrophoresis on 1.2%
agarose gels containing 6% formaldehyde and analysed by blot
hybridization after transfer onto nylon membrane filters (Hybond
N, Amersham). The filters were hybridized with a nick-translated
32P-labelled human stathmin probe [1500-kb SmaI-Clal fragment
ofplasmid p19.6 (Maucuer et al, 1990; Curmi et al, 1994)] in 50%
formamide at 42'C. Membranes were washed in stringent condi-
tions in 0.1 x SSPE (1 x SSPE: 150 mm sodium chloride, 9 mM
sodium phosphate, 1 mM EDTA) and 0.1% SDS at 50°C and
subjected to autoradiography at -80°C. Membranes were rehy-
bridized with a 36B4 cDNA control probe [0.7-kb PstI fragment as
described (Masiakowski et al, 1982)] corresponding to a ubiqui-
tous RNA. This control probe served in each experiment as an
internal reference for the integrity of the RNA preparation and to
normalize the amount of RNA loaded on the gel. The relative
intensity of the mRNA bands was first assessed by visual exami-
nation and then by densitometry. Stathmin transcript levels in
tumours were quantified relative to those in normal breast tissue
by serial dilution oftumour RNA, until the Northern hybridization
signals reached similar intensities. Stathmin transcript levels in
tumours were scored as B (basal), M (moderate) or H (high).
Immunohistochemistry (IHC)
Preliminary experiments on formalin- or Bouin-fixed tissue
sections showed that this material was suitable for use with our
anti-stathmin antiserum. Fixed sections were deparaffinized twice
in xylene, rehydrated through a graded series of ethanols from
100% to 30% and then immersed in tap water. After three 10-min
washes in phosphate-buffered saline (PBS)-glycine 0.1 M, non-
specific binding was blocked by three 10-min incubations in PBS
containing 3% bovine serum albumin (BSA). The primary anti-
stathmin antiserum directed against peptide I of rat stathmin
(Koppel et al, 1990) was applied at a 1:150 dilution to the slides
and incubated overnight at 4°C in a moist chamber. After six
10-min washes with PBS-Tween 0.1%, fluorescein isothiocyanate
(FITC)-conjugated goat anti-rabbit IgG antiserum (Tago, CA,
USA) diluted 1:200 was applied to the slides, which were again
incubated for 1 h at room temperature. After washing (nine 10-min
washes with PBS-Tween 0.1%), slides were mounted with
Mowiol (Mowiol 10%, glycerol 25%, Tris 100 mM). The prepara-
tions were observed with a conventional fluorescence microscope.
A negative control was used for each tumour, with a 100 molar
excess of antigen peptide during the staining procedure to
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neutralize the primary antibody specific binding. Immuno-
histochemistry (IHC) results were analysed by two independent
investigators, discordant results being reviewed together. For
Ki-67 staining, sections were deparaffinized as described above,
washed twice with PBS-glycine 100 mm, then boiled in citrate
buffer pH 6 in a pressure cooker for 4 min. Sections were rinsed in
PBS, and endogenous peroxidase activity was blocked by incuba-
tion for 15 min at room temperature in 0.3% (v/v) hydrogen
peroxide in PBS. Sections were then washed three times in PBS
and incubated with rabbit anti-human Ki-67 antigen at 1:50 dilu-
tion (Dako, Denmark). After three 5-min washes in PBS, the
binding of the primary antibody was visualized with the Dako
LSAB-2 kit. Finally, sections were counterstained with haema-
toxylin then mounted with Aquatex (Merk, France). The Ki-67
labelling index represents the percentage of positively stained
nuclei, reported to the total number of tumour cells (at least 1000
cells by section) counted across photomicrographs of representa-
tive fields ofthe section.
Protein analysis
Protein extraction and quantification
Frozen biopsy specimens were available for protein extraction in a
subset ofseven breast tumours. Samples (6-53 mg) were sonicated
twice for 60 s on ice in 500 tl of extraction buffer (20 mM Tris-
HCI pH 8, 10 ,tg ml-' leupeptin, 25 ,ug ml-' aprotinin, 10 jg ml-'
pepstatin, 1 mm EGTA). The disrupted tissues were centrifuged at
4°C and 100 000 r.p.m. for 6 min in a Beckman TL-100 centrifuge.
Protein was assayed by the method of Bradford (1976) using BSA
as standard.
Polyacrylamide gel electrophoresis
One-dimensional electrophoresis was performed on 13% poly-
acrylamide gels (1D PAGE) (Laemmli, 1970).
Two-dimensional PAGE (2D PAGE) was performed according
to Garrels (1979) with modifications (Sobel and Tashjian, 1983).
Isoelectric focusing gels contained 2% total ampholines
(Pharmacia, Sweden), pH 5-8 and 3.5-10 in the proportion 4:1 for
the analysis of stathmin isoforms. The second dimension was run
on 13% polyacrylamide gels. Proteins were either silver-stained on
fixed gels as previously described, or immunoblotted (see below).
monoclonal antibody against actin (N350, Amersham) was used at
a 1:1000 dilution. Bound antibodies were detected with ECL
(Amersham) and the filters were exposed to XAR5 film (Kodak,
NY, USA).
The integral optical density of stathmin spots on trans-illumi-
nated autoradiograms was measured with a BioProfil (Vilber
Lourmat, France) image analysis system, after background treat-
ment. Absolute quantification of stathmin protein was performed
by comparing the integrated optical density ofthe stathmin band in
tumour extracts with a standard scale constructed using recombi-
nant protein (concentration assayed by amino acid analysis and
measured simultaneously on the same film as experimental
samples). Results with different exposure times differed by less
than 10%. Results are expressed as absolute amounts of stathmin
per arbitrary unit of actin.
Quantification of the relative amounts ofstathmin isoforms
Separation of stathmin isoforms was performed by 2D PAGE. The
amounts loaded on the gels were equilibrated for the total amount
of stathmin in each sample (determined by ID Western blots).
After separation, stathmin isoforms were revealed by Western
blotting as described above. Stathmin isoforms were identified by
comigrating paired tumour samples with a radiolabelled sample
containing most of the known stathmin isoforms. The latter
consisted of extracts from [35S]methionine-labelled PC12 cells
stimulated by nerve growth factor (NGF)/forskolin (2.5 S NGF,
200 ng ml- overnight; forskolin 100 gM for 1 h) (Doye et al,
1990), after immunoprecipitation with an antistathmin antiserum.
Quantification was performed as described above. Results are
expressed as the relative amount of stathmin isoforms in each
tumour.
Statistical analysis
Differences were analysed for statistical significance by using the
chi-square test with Yate's correction to adjust for the continuity
of the chi-squared distribution, when appropriate. Differences
between the two populations were judged significant at a confi-
dence level greater than 95% (P < 0.05).
Quantification of total stathmin in tumours by Western
blotting
Preliminary 1D PAGE separation of equal amounts of tumour
protein revealed that samples contained, in addition to cellular
protein, variable amounts of plasma protein (the prominent visible
variation concerend serum albumin). Use ofthe total protein content
to determine and compare the stathmin content oftumours was thus
inappropriate. Instead, we expressed stathmin content relative to the
amount ofactin (considered as an intracellular reference).
Cell proteins were separated by 13% sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred
onto 0.2-jim nitrocellulose filters (Schleicher & Schuell,
Germany) in a semi-dry electroblotting apparatus (transfer buffer:
48 mM Tris, 39 mM glycine, containing 20% isopropanol). The
membrane was saturated with 5% non-fat dry milk in immunoblot
solution (12 mm Tris-HCl pH 7.4, 160 mm sodium chloride, 0.1I%
Triton X-100) and probed with the same antiserum used for
stathmin detection in IHC, but at a 1:10000 dilution. A mouse
N
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Figure 1 Total RNA extracted from breast specimen from women
undergoing cosmetic breast surgery (N), adjacent normal tissue from breast
cancer patients (P) and breast tumour tissue (T) was electrophoresed on
agarose gels. Northern blotting was performed with the 32P-labelled
stathmin probe. Rehybridization of the blot with the 36B4 probe
demonstrated that comparable amounts of RNA were loaded in each case.
The normal breast tissues (N and P) show a low level of stathmin mRNA
(scored B). Amounts of stathmin mRNA in breast tumours varied from basal
(scored B: T2, T3, T4 and T13) to moderate (scored M: T5 and T8) and
high (scored H: T7)
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Table 1 Comparison between LOH on chromosome 1p32-i pter and
overexpression of stathmin mRNA
1p32-1pter LOH
Stathmin
expression Yes No pa
Basal 13 17 NS
Overexpressing 8 2 P= 0.082
aX2 test; NS, not significant.
A
B M H
TI T2 T3 T5 T6 17
Actl
Stathmin
B
Figure 2 (A) Western blot analysis of stathmin in human breast tumours.
Whole cellular proteins were prepared from frozen biopsies, separated on
SDS-PAGE, electroblotted on nitrocellulose membrane and reacted with anti-
stathmin antiserum and anti-actin monoclonal antibodies as described under
'Patients and methods'. Tumours Ti, T2 and T3 (scored B by Northern
blotting) expressed basal levels of stathmin. Tumours T4 and T5 (scored M
by Northern blotting) expressed moderate levels, whereas tumour T7 (scored
H by Northern blotting) expressed high levels of stathmin. (B) Normalized
expression of stathmin. Normalized expression represents the ratio of
stathmin to actin in each tumour to the mean ratio of stathmin to actin in
normal breast tissue. Three groups of tumours were identified matching the
groups based on stathmin mRNA scoring: (i) tumours Ti, T2 and T3
expressed basal levels of stathmin (basal ratio), (ii) tumours T5 and T6
showed moderate overexpression (ratio of stathmin to actin around 10 times
the basal ratio) and (iii) tumour T7 expressed a high level of stathmin
(stathmin/actin ratio about 75 times above the basal ratio)
RESULTS
Stathmin mRNA expression in normal breast tissue
RNA was extracted from normal breast specimens obtained from
eight women undergoing cosmetic breast surgery and six breast
cancer patients. Northern blot hybridization revealed a clear
stathmin signal with a normal size of 1 kb, which was normalized
to the 36B4 control signal. Stathmin mRNA expression was weak
in all the control specimens and was scored as basal (B) (Figure 1).
Stathmin mRNA overexpression in one-third of breast
tumours
Northern blotting of the 50 human breast carcinomas showed that
all expressed a stathmin mRNA of the normal size. However,
major differences in the amount of stathmin messenger were
observed: 35 tumours scored B (basal), ten gave a signal 3-5 times
that ofnormal breast tissue (scored M) and five gave a greater than
sixfold stronger signal (scored H) (Figure 1). The strongest expres-
sion was 32-fold the basal level in tumour no. T7.
Correlation between stathmin mRNA overexpression
and clinical and pathological parameters
Overexpression of stathmin mRNA was not significantly associ-
ated (X2 analysis) with standard prognostic feature including
macroscopic tumour size, histopathological grade, lymph node or
steroid receptor status (data not shown) and with the Ki-67
labelling index. The last feature showed great variations from
4.7% to 21.2% in tumours scored B, and from 1.9% to 18.5% in
stathmin-overexpressing tumours.
Tentative link between stathmin mRNA levels and
1p32-1pter LOH
Southern blots of restricted genomic DNA with the stathmin
cDNA probe (which is not polymorphic) showed no rearrange-
ment or amplification of the stathmin gene in the overexpressing
tumours compared with the controls in any of the 50 human breast
tumours tested (data not shown).
Forty ofthe 50 tumours have also been tested for LOH with five
polymorphic DNA markers (DlS80, D1S76, D1S7, DlS57 and
MYCLI) located in the lp32-pter region: 21 (52.5%) showed
LOH on the telomeric region, while the remainder had a normal
DNA profile. As shown in Table 1, we found a trend towards a link
between lp32-pter LOH and stathmin mRNA overexpression
(P = 0.082). Indeed, 80% (8/10) of the tumours overexpressing
the stathmin gene showed deletions in the lp32-pter region,
compared with 43% (13/30) ofthe tumours expressing basal levels
of stathmin mRNA.
High stathmin protein expression in tumours with high
stathmin mRNA levels
Stathmin protein expression was investigated in seven tumours for
which frozen samples were available. Four of these tumours
scored B for stathmin mRNA, two scored M and one scored H. We
first evaluated the stathmin content in each of these tumours by
Western blotting of 5 tg of high-speed centrifugation supernatant
protein. A parallel silver-stained gel, run with the same amount of
sample, revealed various degrees of contamination by serum
protein. Blots were thus probed with an anti-actin antibody to
normalize the amount of loaded tissue protein to this cellular
protein marker. As shown in Figure 2A, tumours scoring M and H
by Northern blotting contained far larger amounts of stathmin than
tumours scoring B; tumours scoring M expressed about ten times
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Figure 3 Two-dimensional analysis of stathmin in tumours expressing basal
(row B) or moderate and high levels of stathmin (row M/H) as explained in
'Patients and methods'. A protein extract from 35S-methionine-labelled PC12
cells stimulated by NGF/forskolin was used as control. Stathmin was found
essentially unphosphorylated in all the tumours, migrating as the N isoform
observed in the control specimen. A small amount of stathmin was
phosphorylated in about half the tumours, with no pattern specific to the M/H
subgroup of tumours. The minor spot that appears adjacent to P1 (left side)
for Ti, 2, 3, 5 and 7 is known as the minor,-isoform, an unphosphorylated
post-translational variant of stathmin (Beretta et al, 1 989b)
more stathmin than tumours scoring B. The strongest expression
was about 75 times that in tumours scoring B; this tumour (no. T7)
also contained the highest stathmin mRNA level (Figure 2B).
Stathmin phosphorylation is not related to stathmin
expression levels
Stathmin phosphorylation was examined on Western blots after
separation of stathmin isoforms by 2D PAGE. A reference PC12
cell sample containing the radiolabelled stathmin isoforms N
(major non-phosphorylated form), P1 (stathmin isoform phos-
phorylated at one site) and P2 (stathmin isoform phosphorylated at
two sites) (Beretta et al, 1989b) was co-migrated with the tumour
samples to identify the observed isoforms. Stathmin in tumours
was mainly present as its unphosphorylated isoform N. A variable
amount of protein was phosphorylated and migrated to position
P1. The P1/N ratio ranged from 0.08 to 0.3 (for comparison, the
P1/N ratio was observed between 0.1 and 0.15 in PC12 cells)
(Doye et al, 1990). No pattern of stathmin phosphorylation
specific to stathmin-overexpressing tumours was identified
(Figure 3).
Localization of stathmin overexpression to tumour cell
cytoplasm
Of the 14 tumours studied by IHC, we detected specific immuno-
reactivity in the five tumours which overexpressed stathmin
mRNA. Interestingly, the bulk of stathmin immunoreactivity was
found inside tumour cells (Figure 4), whereas infiltrating lympho-
cytes were found weakly positive or devoid of stathmin immuno-
reactivity. Normal glandular cells isolated in the tumour or in the
normal parenchyma were also unlabelled. Tumour cell labelling
was found exclusively in the cytoplasm, and the staining pattern
consisted either of isolated positive cells or diffuse positivity
throughout the section. Stathmin was never overexpressed in
tumours scoring B by Northern blotting. We thus observed a perfect
match between stathmin mRNA overexpression, high levels of
stathmin by Western blotting and IHC positivity (Table 2).
DISCUSSION
Interest in the study of stathmin in tumours grew with the observa-
tion that stathmin, a 19-kDa cytosolic phosphoprotein, is subject to
marked variations in its expression and phosphorylation pattern
during cell regulation, triggered by signals as diverse as hormones,
growth factors and differentiation factors (Strahler et al, 1992;
Larsson et al, 1995). Recently, attention was raised when it was
discovered that stathmin is a major microtubule-destabilizing
factor in vitro (Belmont and Mitchison, 1996) and in vivo. Both
the overexpression of wild type stathmin or of a cdk target site
mutant elicited rapid depolymerization oftubulin (Marklund et al,
1996). It was also noticed that the overexpression of a non-
phosphorylatable mutant ofstathmin resulted in a large population
of cells blocked at G2/M with a high DNA content (Marklund et
al, 1994b; Larsson et al, 1995; Lawler et al, 1997). To account for
these effects, we demonstrated that stathmin directly interacts
with, and sequesters, tubulin (Curmi et al, 1997) in a T2S complex
(Jourdain et al, 1997), and that this sequestration leads to the
displacement of the microtubule/tubulin equilibrium towards
depolymerization of microtubules (Jourdain et al, 1997).
Importantly, phosphorylation of stathmin altered the affinity of
stathmin for tubulin (Marklund et al, 1996; Curmi et al, 1997; Di
Paolo et al, 1997; Horwitz et al, 1997; Larsson et al, 1997).
Together, these results give insight into the observed physiological
variations of stathmin phosphorylation during the mitotic cycle
(Strahler et al, 1992; Brattsand et al, 1994) and argue for the search
for stathmin dysregulations in tumours as well as an understanding
ofits mechanisms.
In the present study, using genomic DNA, mRNA and protein
analysis, we assessed, for the first time, stathmin expression in
human breast cancer. The main finding was that there is a strong
expression of stathmin mRNA and protein in one-third of the
tumours examined. Among the 50 breast tumours studied, 15 over-
expressed stathmin mRNA (3-32 times basal values), with protein
levels ranging from 10 to 70 times the basal value. This over-
expression, also assessed by immunohistochemistry, was
contributed almost exclusively by cancer cells, with immunoreac-
tivity localized exclusively in the cytoplasm. The results of these
three methods is in good agreement, as a correlation is observed
between high levels of stathmin mRNA and high stathmin protein
content. This indicates that any of the three methods used here
could be employed as a screening tool for larger studies. Stathmin,
in overexpressing tumours, is found mainly in its unphosphory-
lated form N, the potentially active form for its interaction with
tubulin. This finding, which may have an important pathophysio-
logical significance, is presently under investigation.
There have been conflicting data concerning stathmin over-
expression in malignant processes. Our results show that stathmin
overexpression in breast cancer is not a constant feature, a trait
already found in other hormone-dependent cancers, such as
prostate adenocarcinomas (Friedrich et al, 1995), and in neuroblas-
tomas (Hailat et al, 1990). On the other hand, stathmin is found to
be more abundant in acute leukaemias of different lineages than
in non-leukaemic cells (Hanash et al, 1988). For breast cancer,
stathmin overexpression may thus delineate a new subgroup of
tumours.
With regard to the possible link between stathmin overexpres-
sion and tumour cell proliferative potential, we measured the Ki-
67 labelling index in tumours and we were not able to correlate
this with stathmin expression. This latter observation might be
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Figure 4 Two breast invasive carcinomas scored H and considered as diffusely positive (A, C, E and B, D, F respectively) are presented after
haematoxylin-eosin and saffron staining (A,B), and immunohistochemical detection of stathmin (C,D). The peptide absorbed anti-stathmin antiserum was used
as a control (E,F) (bar = 40 pm). The tumour on the left displays a massive and trabecular paftern of tumour proliferation (A). Immunohistochemical detection of
stathmin (C) shows positive cytoplasmic staining in the breast carcinoma cells, the tumour cell nuclei remaining unstained (arrow). The negative control (E)
shows no reactivity in the previously immunostained tumour cells. The tumour on the right is from a carcinoma with isolated tumour cells or nests of tumour cells
in a stroma rich in lymphocytes (B). Immunohistochemical detection of stathmin (D) is found in the cytoplasm of tumour cells (arrow). The negative control (F)
shows no reactivity in the previously immunostained tumour cells
because of the usually large variations found with this marker
(Bouzubar et al, 1989). Studies on larger series will answer this
question. Data relating stathmin expression and the proliferation
potential of tumours reported in the literature are, apparently,
somewhat confusing. In natural conditions, up-regulation of
stathmin has been found to be neither uncoupled from cell prolif-
eration nor restricted to cell types with proliferative potential
(Brattsand et al, 1993). In non-Hodgkin's lymphoma and in
Hodgkin's disease, Hodgkin and Reed-Sternberg cells frequently
express stathmin with strong staining intensity, but stathmin over-
expression is only partly related to cell proliferation (Nylander et
al, 1995). In contrast, stathmin transfection into lymphoblastoid
cells results in a partial inhibition ofcell proliferation (Brattsand et
al, 1993), and antisense transfection into leukaemic cells reverses
the malignant phenotype (Jeha et al, 1996).
To interpret these observations, one must consider that stathmin
is at the heart of a complex signalling network, being a direct
substrate for different kinases: the MAP kinase family (Leighton
British Journal of Cancer (1998) 78(6), 701-709
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Table 2 Summary of the results for stathmin expression and
phosphorylation
Tumour no. Northern WB IHC 2DWB
Tl B 1 ud N
T2 B 1 ud NP
T3 B 1 ud NP
T4 B 1 ud N
T5 M 9 + N
T6 M 13 + N
T7 H 77 + NP
T8 M ND + ND
T9 M ND + ND
T10 B ND UD ND
T1l B ND UD ND
T12 B ND UD ND
T13 B ND UD ND
T14 B ND UD ND
By Northern blotting, tumours were scored basal (B), moderate (M) or high
(H). Western blotting (WB) showed basal levels of stathmin (1) or increased
levels (ranging from 10 to 77 times the basal value; values are expressed as
defined in Figure 2). Immunohistochemical studies (IHC) showed tumours
with no stathmin reactivity (ud) or specific stathmin labelling in tumour cells
(+). Note that a perfect match was found for stathmin expression at the
mRNA and protein levels (Northern, WB and IHC). Stathmin phosphorylation
was examined after separation of stathmin isoforms by 2D-PAGE as
described in Figure 3. No specific pattern of stathmin phosphorylation was
observed for basal or overexpressing tumours. N, stathmin essentially in its
unphosphorylated state; NP, stathmin displaying a significant proportion of its
P1 phosphorylated form in addition to its unphosphorylated state. B, basal;
UD, undetectable; N, 0.08 < P/N <0.15; M, moderate; ND, not determined;
NP, 0.15 < P/N< 0.30. H, high
et al, 1993), cAMP-dependent protein kinase (Beretta et al, 1993),
p34cdc2 kinase (Beretta et al, 1993; Brattsand et al, 1994; Larsson
et al, 1995) and the Ca2+-calmodulin-dependent kinases II and IV
(Marklund et al, 1994a; Le Gouvello et al, 1998). Furthermore,
stathmin interacts with various protein partners, for which we have
identified several candidates (Maucuer et al, 1995). One of these,
CC2/tsg1O1, interestingly being the product of a tumour sucepti-
bility gene (Li and Cohen, 1996), was suggested to be implicated
in breast cancer (Li et al, 1997). The intricate regulation of
stathmin and of its partners being highly probable, we speculate
that stathmin overexpression might contribute to tumorigenesis in
different ways.
1. it could represent a normal reaction to cell proliferation itself.
In fact, a recent study in our laboratory showed that a high cell
density in culture induces stathmin expression, most likely
triggered by cell-cell contacts. Stathmin expression, in that
case, is likely being up-regulated, in relation to the limitation
ofcell overgrowth at the stage preceding cell differentiation
(Balogh et al, 1996). This cell culture result is in good agree-
ment with the induction of stathmin expression during liver
regeneration, stathmin displaying a delayed expression peak
following the mitotic peak and correlating with the slowdown
in cell proliferation (Koppel et al, 1993). Stimulated expres-
sion of stathmin may thus be part of a regulatory programme
aimed at limiting cell overproliferation, and also activated,
although inefficiently, in transformed tumoral cells.
2. Alternatively, overexpression of stathmin might reflect an
alteration of stathmin itself, leading to the malignant pheno-
type; mutations in the structural gene that are undetectable by
blotting techniques would then remain to be identified.
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3. Finally, cells might react to changes in stathmin protein
partners (Maucuer et al, 1995) in a feedback pathway.
The other interesting finding in this study is the tentative link
between loss of heterozygosity in the lp32-lpter region and
stathmin overexpression. Deletions of the short arm of chromo-
some 1, especially the telomeric lp32-pter region, have been
detected by both molecular and cytogenetic approaches in breast
tumours, suggesting that this region contains a breast tumour-
suppressor gene (Bieche et al, 1994). Interestingly, this region
also houses the stathmin gene (mapping to lp35-36.1). Stathmin
appears thus to be a good candidate for being one of the tumour
suppressor genes located in this chromosome region. The finding
of a tentative link between LOH in the 1p32-lpter region and
stathmin overexpression may appear surprising, but it is reminis-
cent of the coexistence of p53 gene LOH and overexpression of
the corresponding protein. In this case, mutations were found
either in the regulatory or in the coding region of the p53 gene
(Aka et al, 1993; Ohgaki et al, 1993; Greenblatt et al, 1994).
Similar mutations may have occurred in the vicinity of or within
the stathmin gene. Alternatively, DNA removal may have brought
a powerful enhancer close to the stathmin gene to account for the
increase in mRNA levels.
In conclusion, our study has clearly established that a significant
proportion of breast cancers overexpress stathmin and may define
a new breast cancer subtype. Further studies with a larger popula-
tion and longer follow-up will allow the evaluation of the
prognostic significance of stathmin overexpression, as well as an
exploration of the status of the stathmin protein partners in the
overexpressing tumours.
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